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BRIEF REPORT
ABSTRACT
Background: Studies have revealed controversial results regarding the diagnostic 
accuracy of plasma α-synuclein levels in patients with Parkinson’s disease (PD). This study 
was aimed to analyze the diagnostic accuracy of plasma α-synuclein in PD versus healthy 
controls and patients with essential tremor (ET).
Methods: In this cross-sectional study, we included de novo (n = 19) and advanced PD 
patients [OFF (n = 33), and On (n = 35) states], patients with ET (n = 19), and controls 
(n = 35). The total plasma α-synuclein levels were determined using an ELISA sandwich 
method. We performed adjusted multivariate regression analysis to estimate the 
association of α-synuclein levels with group conditions [controls, ET, and de novo, OFF 
and ON-PD]. We studied the diagnostic accuracy of plasma α-synuclein using the area 
under the curve (AUC).
Results: The plasma α-synuclein levels were higher in controls compared to PD and ET (p 
< 0.0001), discriminating de novo PD from controls (AUC = 0.74, 95% CI 0.60–0.89), with a 
trend towards in advanced PD (OFF state) from ET (AUC = 0.69, 95% CI 0.53–0.84).
Conclusions: This is the first study examining and comparing plasma α-synuclein levels in 
ET vs. PD and controls. Preliminary findings suggest that plasma α-synuclein levels might 
help to discriminate de novo and advanced PD from controls and ET.
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BACKGROUND
Parkinson’s disease (PD) is well characterized for the 
pathological presence of α-synuclein (α-syn) aggregates 
in Lewy bodies. α-syn is considered a promising candidate 
as a biomarker for diagnosing PD, mainly because some 
of the non-motor early symptoms, such as constipation, 
depression, and anosmia, might be related to α-syn 
inclusions within the related tissues [1]. In non-parkinsonian 
disorders such as essential tremor (ET), the focal presence 
of Lewy Bodies in the locus coeruleus has been reported 
[2].
The majority of studies on levels of different α-syn 
subtypes, including total, oligomeric, and phosphorylated 
form in body fluids, have been conducted for the 
cerebrospinal fluid [3]; however, only a few PD studies have 
investigated α-syn levels in plasma [4]. The results of that 
plasma α-syn between PD patients and healthy controls 
have been controversial [5], and to our knowledge, there 
is no data on peripheral α-syn levels in ET. This study was 
therefore aimed to study the discriminative diagnostic 
accuracy of plasma α-syn in PD versus controls and ET.
METHODS
DESIGN, PARTICIPANT CHARACTERISTICS AND 
ASSESSMENTS
This cross-sectional, case-control, pilot, observational 
study was approved by the Burgos and Soria Health Area 
Institutional Review Board. Written informed consent was 
obtained from all subjects. We included a consecutive 
sample of non-demented patients with PD, ET, and healthy 
control subjects with a Mini-Mental State Examination 
[MMSE] ≥ 26) [6, 7], followed in a movement disorder clinic 
at Burgos University Hospital. Patients were diagnosed with 
idiopathic PD according to the UK PD Society brain bank 
criteria [8], including de novo PD and more advanced PD 
in both conditions, on the OFF-state (early morning before 
PD medication and approximately 12 hours after the last 
dose the night before), and ON-state (1 hour after taking 
their regular PD medication). The severity of PD motor 
symptoms was assessed by using the motor subscale of 
the Unified Parkinson’s Disease Rating Scale (mUPDRS) [9], 
global burden of non-motor symptoms (NMS) using the 
NMS Scale for PD (NMSS) [10], and cognitive impairment 
using the Parkinson’s Disease Cognitive Rating Scale 
(PDCRS) [11]. The diagnosis of ET was established based on 
the ET international criteria [12]. De novo PD diagnosis was 
supported by [123I]FP-CIT SPECT imaging showing dopamine 
degeneration. Sociodemographics, bio-specimens, and 
clinical data collection were obtained in one visit. Control 
subjects were excluded if they were diagnosed with any 
other neurological disorders or had a family history of 
neurodegenerative diseases.
DETERMINATION OF α-SYNUCLEIN
The blood samples were collected into commercially 
available anticoagulant-treated tubes containing EDTA 
(BD VacutainerTM). After collection, the tubes were labelled 
and immediately centrifuged for 15 min at 2000 g in a 
refrigerated centrifuge Allegra X-30-R (Beckman Coulter 
Inc.) to remove cells and platelets. The plasma samples 
were then transferred to Eppendorf tubes in aliquots of 500 
μL and stored at –80°C until analysis.
The ELISA method was as follows. In brief, 100 μL of 
a concentration of 1 μg/ml of anti-human α-syn mouse 
monoclonal antibody S5566 clone Syn211 (Sigma-Aldrich, 
Inc, US) was used as capture antibody to coat Microlon® 
96 well microplates of half area high binding (Greiner Bio-
One, GmbH, Germany) in 50 mM Na2CO3/NaHCO3 coating 
buffer pH 9.6 overnight at 4°C. After washing the plate 
four times with PBST (phosphate borate saline buffer with 
0.05% Tween 20, pH 7.4), non-specific sites were blocked 
with 100 μL of blocking buffer at 37°C for 1 h (phosphate 
borate saline buffer – PBS- pH 7.4 with 2% casein). After 
another washing step, 100 μl of plasma samples diluted 
ten times in PBST were added to the wells and analyzed in 
duplicates. Appropriate standards of recombinant human 
α-syn expressed in E. coli S7820 (Sigma-Aldrich, Inc. US) 
were prepared in the range of 0.625–300 ng/ml in PBST 
and included in each plate. A total of twelve calibration 
points were used in duplicates, counting blanks. The plates 
were incubated at 37°C for 1.5 h in order to perform the 
capturing step. A washing step followed in the same 
conditions as mentioned before. Detection antibody was 
a polyclonal anti-human α-syn produced in rabbit S3062 
(Sigma-Aldrich, Inc. US) using as immunogen a synthetic 
peptide corresponding to a C-terminus sequence (amino 
acids 111–132 with a C-terminally added lysine). This 
sequence has no homology with β and α-synuclein making 
this polyclonal antibody highly specific to α-syn. Incubation 
at 37°C for 1 h was done so the polyclonal antibody (100 
μL, dilution 1:5000) could bind the α-syn fixed to the 
monoclonal antibody. After an additional washing step, 
100 μL of dilution 1:1000 secondary antibody anti-rabbit-
HRP conjugated (horse-radish peroxidase) A6154 (Sigma-
Aldrich, Inc. US) was added and left stand in incubation at 
37°C for 1 h. A final washing step was performed, and the 
bound HRP activity was assayed using 100 μL of colorimetric 
reagent with o-phenilendiamine (OPD) as a substrate 
during 20 min incubation at 37°C. The enzymatic reaction 
was stopped by the addition of 50 μL H2SO4 2 M, and the 
plates read at 492 nm within 30 min in a SynergyTM HT 
plate reader (BioTek Instruments, VT, US).
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Concentration estimates of total α-syn in the samples 
run in duplicates were calculated according to the standard 
curve obtained in each plate, taking into account the 
dilution factor. The same lot of standards was used each 
time in order to minimize inter-assay variability. Calibration 
curves were included in each ELISA plate and adjusted to 







y d  (Eq. 1)
where y is the OD at 492 nm, x the concentration in ng/ml 
and a, b, c and d the adjusted parameters.
The method was validated by checking the following 
parameters. The limit of detection (LOD) was 0.7 ng/mL 
of α-synuclein. The reproducibility assay showed a sum 
of squares error for the calibration curves less than 10%. 
Additionally, the repeatability of the method was measured 
20 times with known concentrations of α-synuclein (1.25; 
5; 20 and 50 ng/mL) with the coefficient of variation <10% 
for all samples. The matrix effect was minimized by diluting 
the plasma ten times prior to analysis, and a standard 
addition assay (with 0, 10, 15, and 25 ng/mL of α-synuclein) 
indicated good recoveries in the range of 100 ± 5%.
STATISTICAL ANALYSIS
The statistics software, IBM SPSS Statistics 19 and 
Statgraphics Centurion XVII, were used for the analysis of 
the data. Normal distribution of the variables was analyzed 
using the Kolmogorov-Smirnov test. Descriptive analysis of 
the participants’ characteristics was performed in terms of 
frequencies (percentage), mean/median values with the 
corresponding standard deviation or interquartile range, as 
appropriate, and 95% confidence intervals. Based on the 
median distribution of the age, individuals were classified 
as younger and older participants. The median values 
of α-synuclein were compared using the Kruskal-Wallis 
(several groups), Mood’s and T-Student tests, based on the 
normal distribution of the data. The pairwise comparisons 
between groups were performed using the Bonferroni 
procedure, pointing out statistically significant differences, 
and Box-and-Whisker plots. The area under the curve (AUC) 
of the plasma α-syn levels according to the distribution of 
their concentrations and the diagnosis of PD (de novo, OFF-
PD, ON-PD) vs. ET and controls was used as a measurement 
of diagnostic accuracy. In this study, we selected an AUC > 
0.70 as an indicator of an adequate ability to discriminate 
between disease conditions [13]. We performed linear 
multivariate regression analysis to estimate the association 
of α-synuclein levels with group conditions (ET, de novo PD, 
OFF-PD, ON-PD) with the control group as the reference 
group, adjusted for age and gender.
RESULTS
A total of 35 healthy controls, 19 de novo-PD, 35 patients 
with advanced disease evaluated during the ON state 
(n = 35) and OFF state (n = 33), and 19 ET patients were 
included. The comparison of clinical characteristics of 
participants are presented in Table 1. There was a higher 
proportion of females in the control group than in the other 
groups (p = 0.01), and patients with ET were older than 
controls (p = 0.002). Overall, the plasma α-syn levels were 
weakly, inversely correlated with age (rs = –0.24, p = 0.004). 
In PD, the plasma α-syn levels were weakly correlated with 
the PDCRS (rs = 0.28, p = 0.01) and moderately, inversely 
correlated with mUPDRS-III scores (rs = –0.38, p = 0.03).
Table 1 Comparison of participant’s characteristics.
Values are expressed in medians (interquartile range) otherwise specified *= mean (Standard deviation). Parkinson’s disease (PD) 
(total sample = 35) measured in the ON state (ON-PD) (n = 35) and OFF state (OFF-PF), (n = 33); ET = Essential Tremor; UPDRS = Unified 
Parkinson’s disease Rating Scale; NMSS = Non motor symptoms severity score: PDCRS = Parkinson’s disease cognitive rating scale. Data 
was compared using the ANOVA test (several groups) and the Mann-Whitney U test (2 groups).





N=19 N=35 P VALUE
Males (%) 13 (68) 24 (69) 22 (67) 12 (63) 11 (31) 0.01
Age (years)* 66.9 (8.8) 64.5 (9.1) 64.1 (9.0) 70.8 (6.7) 61.4 (7.3) 0.002
Disease duration (years) 1 (0.6; 3) 10 (2; 25) 10 (2; 25) 7 (1; 29) - -
UPDRS-III score 20 (8; 41) 24 (5; 49) 35 (12; 70) - - 0.01
NMSS total score 42 (24; 86) 69 (12; 119) 69 (12; 119) - - 0.08
PDCRS total score 74 (58; 112) 80 (43; 109) 69 (12; 119) - - 0.91
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The quantitative results for plasma α-syn obtained 
by means of a sandwich ELISA are shown in Figure 1.A. 
The median value for the control group was 163.03 
ng/ml, which was higher than those of the other groups 
(de novo-PD = 86.11 ng/ml; OFF-PD = 138.45 ng/ml; ON-PD 
= 100.65 ng/ml and ET = 79.65 ng/ml). The Kruskal-Wallis 
test indicated that all α-syn mean values were significantly 
different (p-value = 0.001 at 95% confidence level), with 
the same result obtained by the Mood’s median test 
(p-value = 0.01). When the Bonferroni correction was 
applied to the pairwise comparisons between groups, the 
α-syn level in the control group was significantly different 
from de novo-PD, ON-PD, and ET groups. Nevertheless, no 
statistically significant differences were observed between 
PD (OFF, ON, de novo-PD) vs. ET. This can be graphically 
observed in Figure 1.B, where the Box-and-Whisker plot 
shows overlapping notches for the control and OFF boxes 
but non-overlapping notches for the control box compared 
to the de novo, ON-PD, and ET groups. Overall, plasma α-syn 
levels were similar in terms of age and gender (Table 2). 
However, stratified pairwise comparisons (Table 2) showed 
that in men, plasma α-syn levels were higher in controls 
Figure 1 A) Scatterplot for the plasma α-synuclein quantitation (ng/ml) for each group. B) Box-and-Whisker plot for plasma α-synuclein 
levels in each group. The median is represented by the vertical line, and a plus sign indicates the mean value. The notch indicates the 95%  
confidence intervals for the medians. Outside points are also represented. NOVO = de novo-PD; OFF = Parkinson’s disease (OFF state); 
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(1)(5)/ (3)(4)/ (3)(5) (1)(2)/ (1)(3) <0.05* (1)(2)/ (1)(4)/ (3)(4) n.s <0.05*
Table 2 Plasma α-synuclein quantitation (ng/ml) stratified by age and gender.
SD = Standard deviation. Age was stratified based on the median distribution of the total sample.*Pairwise group comparisons. n.s. = not 
significant.
5Albillos et al. Tremor and Other Hyperkinetic Movements DOI: 10.5334/tohm.600
than ET, and OFF-PD than de novo-PD and ET; in women, 
plasma α-syn levels were higher in controls than ON and 
OFF-PD; in young participants (<66 years old) plasma α-syn 
levels were higher in controls than ON-PD and de novo-PD, 
and OFF-PD than ET. Gender and age-adjusted multivariate 
regression analysis (Table 3), showed that compared to 
controls, α-syn levels were lower in PD (On, Off and de 
novo-PD) and ET.
In ROC analysis, α-syn levels were able to discriminate 
between 1) de novo-PD from controls with an AUC = 0.74, 
(95% CI 0.60–0.89), and a cut-off α-syn level of 87.65 ng/ml, 
positive predictive value (PPV) of 0.76 (95% CI 0.59–0.88), 
negative predictive value (NPV) of 0.62 (95% CI 0.36–0.82); 
2) ET from controls with an AUC = 0.74, (95% CI 0.61–0.88), 
a cut-off α-syn level of 85.80 ng/ml, PPV of 0.73 (95% CI 
0.40–0.92), NPV of 0.76 (95% CI 0.60–0.86); with a trend 
towards discriminating between 1) OFF-PD from controls, 
with an AUC = 0.64, (95% CI 0.50–0.77), and a cut-off α-syn 
level of 182.03 ng/ml, 2) OFF-PD from de novo-PD, with an 
AUC = 0.68, (95% CI 0.52–0.83), and a cut-off α-syn level 
of 111.83 ng/ml; and 3) OFF-PD from ET, with an AUC = 
0.69, (95% CI 0.53–0.84), and a cut-off α-syn level of 83.71 
ng/ml. α-syn levels did not discriminate de novo-PD from 
ET, and ON-PD from ET and OFF-PD.
DISCUSSION
The association between ET and PD has frequently 
been reported [14]. It is well known that a subgroup of 
patients with ET develops parkinsonian disturbances [15]. 
On the contrary, action tremor may occur in patients 
with PD causing misdiagnosis with ET [16, 17]. Given the 
overlapping clinical manifestations and pathology, the 
differentiation between PD and ET is difficult [18]. Currently, 
to differentiate PD from ET, we can use [123] I-FP-CIT SPECT 
[19], or transcranial sonography of the substantia nigra 
[20], not always available in clinical facilities. Moreover, 
other procedures such as electrophysiology cannot be 
used as an accurate diagnostic tool for ET given the wide 
range of allowable frequency of tremors from 4 to 12 Hz 
[18]. In terms of fluid biomarkers, to our knowledge, no 
reliable biomarker for distinguishing PD from ET has been 
investigated.
In this study, we found that, firstly, in adjusted multivariate 
analysis, total α-syn levels in plasma were higher in controls 
compared to PD and ET; secondly, increased α-syn levels 
in plasma might differentiate advanced PD (OFF state) 
from ET, and de novo-PD, suggesting that capacity of 
α-syn levels to differentiate PD and ET is influenced by the 
progression of PD; thirdly, the α-syn levels in plasma did not 
differentiate ON vs. OFF states, demonstrating that the PD 
motor state and the time of the medication intake should 
not be an important confounder; and fourthly, α-syn levels 
might differentiate de novo vs. more advanced PD. Post-
hoc analysis (age and gender intra-group comparisons) 
also demonstrated differences between controls vs. PD 
and ET. However, our results should be taken with caution, 
given the lack of adjustment for multiple comparisons due 
to the overall exploratory approach of the analysis and the 
absence of comparable preliminary data in ET.
In PD biomarker literature, there is a high heterogeneity 
across plasma α-syn studies. Whereas some studies have 
found a reduction of α-syn levels in plasma via ELISA 
detection for the non-carriers and carriers of mutation 
LRRK2 [21], other studies have found similar α-syn levels 
[22], or higher α-syn levels in patients with PD [5] and 
other parkinsonian disorders such as Multiple System 
Atrophy compared to controls [23]. These differences 
across PD studies could be attributed to the co-existence 
of several components such as assays, disease staging, 
disease duration, and study setting that may influence 
the measurement. The discrepancy of results in the 
literature and the difficulties of interpreting the value 
N =136
REFERENCE GROUP = CONTROL
B COEF. IC95% p-VALUE
ON-PD –47.83 (–79.33, –16.33) 0.003
OFF-PD –32.02 (–63.83, –0.20) 0.049
NOVO-PD –53.50 (–90.57, –16.42) 0.005
ET –53.28 (–92.84, –13.71) 0.009
Gender (Men) –22.15 (–45.33, 1.03) 0.06
Age (>=66) –15.06 (–38.26, 8.15) 0.20
Cons 182.50 (159.17, 205.83) <0.001
Table 3 Clinical variables associated with Plasma α-synuclein levels.
Adjusted R2: 15,1%.
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of plasma α-syn could be explained by 1) the fact that 
the peripheral origin of α-syn could be from red cells 
due to hemolysis [24], and the α-syn content may be 
overestimated; 2) disparities in methods of analysis, and 
the sensitivity or specificity of antibodies (total α-syn, 
oligomeric or modified via phosphorylation α-syn, or even 
specific isoforms) [25]; 3) the difficulties of controlling the 
necessary standardization of the protein and its degree 
of oligomerization [3]; 4) the interference of heterophilic 
antibodies present in up to 40% of the population, which 
have affinity for animal antibodies [26], and oligomeric 
detection due to the competition of monomers if the 
same antibody is used for capture and detection, reducing 
the number of oligomers quantified [27]; and 5) the 
interference of endogenous peroxidases and alkaline 
phosphatases present in blood components, as these 
endogenous enzymes may increase the assay background. 
To overcome methodological bias in determining the value 
of plasma α-syn, our methodology was in-house, carefully 
described, and the measurements were all performed in 
duplicates and validated.
Our study has some limitations, including the small 
sample size of patients and a cross-sectional design. On 
the other hand, our results were obtained from a single-
center, and the biosamples were standardly collected 
and analyzed in all participants, decreasing collection and 
measurement bias. In addition, our study can be useful for 
prompting further studies with larger sample cohorts that 
will allow to determine whether α-syn levels in plasma have 
a diagnostic capacity to discriminate between predominant 
tremor phenotype of PD from ET. We have also highlighted 
the importance of providing detailed information on how 
and when the plasma α-syn is collected, in terms of PD 
severity (de novo vs. advanced PD), and time (OFF vs. ON 
state), in order to establish standard protocols.
In sum, the current study provides evidence in support 
of the possibility that α-syn levels in plasma might help to 
differentiate PD from controls and advanced PD from ET. 
There is no doubt that for biomarker development applied 
to large tremor populations, the field should evolve into an 
era of etiologically defined tremor disorders.
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